A Phase 3 interventional study of Ranibizumab 0.5 mg and Sham injection in Macular Edema Secondary to Branch Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 14th largest by enrollment, is one of 10 that started in 2013, is one of 25 in phase 3, and was the 52nd registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 10 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 283 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
39 studies in Macular Edema by Novartis: none open now, none under way, none of them phase 3. Of 37 finished, 25 (68%) have results posted.
Among the 39 studies in Macular Edema by Novartis, this one is the 11th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 19th registered.
Novartis’s Macular Edema studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Novartis’s 39 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRN Intravitreal injection
Drug: Ranibizumab 0.5 mg
As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
Other: Sham injection
intravitreal injection of 0.05 ml
Sham intravitreal injection
Also known as: Sham
Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 6 and compared to Baseline.
Time frame: Baseline to Month 1 through Month 6
Average Change of Best Corrected Visual Acuity (BCVA) in Patients From Baseline to Month 1 Through Month 12
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline
Time frame: Baseline to Month 1 through Month 12
Best Corrected Visual Acuity (BCVA) Change Over Time
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline
Time frame: Month 1 through Month 12
Number of Participants With a Best Corrected Visual Acuity (BCVA) Improvement of ≥5, ≥10, ≥15, and ≥30 Letters Over Time
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters
Time frame: Baseline to month 12
Number of Participants With Best Corrected Visual Acuity (BCVA)Loss of 15 Letters in the Study Eye
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.
Time frame: Baseline to 12 months
Change in Central-Sub-Field- Thickness (CSFT) Over Time
OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center
Time frame: Month 1 to month 12
Change in Total Area of Fluorescein Leakage (Center Subfield) From Baseline Over Time
Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes
Time frame: month 3, 6 and 12
Change in Total Area of Fluorescein Leakage (Inner Subfield) From Baseline Over Time
Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes
Time frame: Months 3, 6 and 12
Change in Total Area of Fluorescein Leakage (Outer Subfield) From Baseline Over Time
Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes
Time frame: Months 3, 6 and 12
Change From Baseline in NEI-VFQ-25 Composite and Subscale Scores at Month 3, Month 6 and Month 12
The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.
Time frame: Baseline, months 3, 6 and 12
| Milestone | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Started | 190 | 93 |
| Completed 6 months | 185 | 91 |
| Discontinued study prior to 6 months | 5 | 2 |
| Completed | 177 | 89 |
| Not completed | 13 | 4 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Adverse event | 5 | 1 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 6 and compared to Baseline.
| Letters | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 | 12.5 ± 8.34 | 5.0 ± 9.18 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline
| Letters | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Average Change of Best Corrected Visual Acuity (BCVA) in Patients From Baseline to Month 1 Through Month 12 | 14.0 ± 8.99 | 7.7 ± 9.41 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from month 1 to month 12 and compared to Baseline
| Letters | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1 | 9.5 ± 8.26 | 1.7 ± 8.70 |
| Month 2 | 11.7 ± 8.39 | 3.7 ± 8.81 |
| Month 3 | 12.9 ± 8.81 | 5.1 ± 10.10 |
| Month 4 | 13.4 ± 9.72 | 6.0 ± 10.44 |
| Month 5 | 13.6 ± 10.24 | 6.5 ± 11.53 |
| Month 6 | 14.0 ± 10.75 | 7.0 ± 12.75 |
| Month 7 | 14.7 ± 10.62 | 8.5 ± 10.97 |
| Month 8 | 14.9 ± 10.52 | 10.4 ± 10.97 |
| Month 9 | 14.8 ± 10.43 | 10.3 ± 10.78 |
| Month 10 | 15.8 ± 10.67 | 11.2 ± 11.12 |
| Month 11 | 15.8 ± 10.42 | 11.1 ± 10.48 |
| Month 12 | 16.4 ± 10.95 | 11.3 ± 11.11 |
Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters
| Participants | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1 Gain of >=5 letters | 139 | 33 |
| Month 1 Gain of >=10 letters | 86 | 12 |
| Month 1 Gain of >=15 letters | 43 | 3 |
| Month 1 Gain of >=30 letters | 2 | 0 |
| Month 2 Gain of >=5 letters | 156 | 44 |
| Month 2 Gain of >=10 letters | 113 | 21 |
| Month 2 Gain of >=15 letters | 72 | 6 |
| Month 2 Gain of >=30 letters | 6 | 2 |
| Month 3 Gain of >=5 letters | 162 | 49 |
| Month 3 Gain of >=10 letters | 116 | 29 |
| Month 3 Gain of >=15 letters | 76 | 16 |
| Month 3 Gain of >=30 letters | 8 | 0 |
| Month 4 Gain of >=5 letters | 159 | 55 |
| Month 4 Gain of >=10 letters | 122 | 32 |
| Month 4 Gain of >=15 letters | 83 | 16 |
| Month 4 Gain of >=30 letters | 11 | 2 |
| Month 5 Gain of >=5 letters | 159 | 60 |
| Month 5 Gain of >=10 letters | 127 | 40 |
| Month 5 Gain of >=15 letters | 83 | 19 |
| Month 5 Gain of >=30 letters | 15 | 2 |
| Month 6 Gain of >=5 letters | 163 | 58 |
| Month 6 Gain of >=10 letters | 129 | 47 |
| Month 6 Gain of >=15 letters | 88 | 25 |
| Month 6 Gain of >=30 letters | 16 | 3 |
| Month 7 Gain of >=5 letters | 162 | 63 |
| Month 7 Gain of >=10 letters | 135 | 49 |
| Month 7 Gain of >=15 letters | 93 | 28 |
| Month 7 Gain of >=30 letters | 16 | 3 |
| Month 8 Gain of >=5 letters | 168 | 66 |
| Month 8 Gain of >=150 letters | 130 | 52 |
| Month 8 Gain of >=15 letters | 94 | 33 |
| Month 8 Gain of >=30 letters | 17 | 4 |
| Month 9 Gain of >=5 letters | 163 | 67 |
| Month 9 Gain of >=10 letters | 139 | 52 |
| Month 9 Gain of >=15 letters | 90 | 32 |
| Month 9 Gain of >=30 letters | 17 | 4 |
| Month 10 Gain of >=5 letters | 169 | 68 |
| Month 10 Gain of >=10 letters | 143 | 53 |
| Month 10 Gain of >=15 letters | 97 | 37 |
| Month 10 Gain of >=30 letters | 22 | 7 |
| Month 11 Gain of >=5 letters | 172 | 67 |
| Month 11 Gain of >=10 letters | 141 | 56 |
| Month 11 Gain of >=15 letters | 103 | 36 |
| Month 11 Gain of >=30 letters | 19 | 4 |
| Month 12 Gain of >=5 letters | 171 | 72 |
| Month 12 Gain of >=10 letters | 142 | 56 |
| Month 12 Gain of >=15 letters | 105 | 36 |
| Month 12 Gain of >=30 letters | 24 | 5 |
Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.
| Participants | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1, Loss of < 15 letters | 188 | 89 |
| Month 2, Loss of < 15 letters | 189 | 90 |
| Month 3, Loss of < 15 letters | 189 | 88 |
| Month 4, Loss of < 15 letters | 189 | 88 |
| Month 5, Loss of < 15 letters | 189 | 88 |
| Month 6, Loss of < 15 letters | 188 | 89 |
| Month 7, Loss of < 15 letters | 188 | 91 |
| Month 8, Loss of < 15 letters | 188 | 92 |
| Month 9, Loss of < 15 letters | 187 | 93 |
| Month 10, Loss of < 15 letters | 188 | 92 |
| Month 11, Loss of < 15 letters | 187 | 93 |
| Month 12, Loss of < 15 letters | 187 | 91 |
OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center
| µm | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 1 | -261.1 ± 171.95 | -42.4 ± 171.88 |
| Month 2 | -274.8 ± 174.17 | -93.1 ± 187.14 |
| Month 3 | -282.2 ± 175.86 | -155.3 ± 209.37 |
| Month 4 | -254.7 ± 183.87 | -193.2 ± 221.58 |
| Month 5 | -258.6 ± 180.57 | -203.2 ± 218.02 |
| Month 6 | -264.1 ± 168.64 | -206.6 ± 221.85 |
| Month 7 | -265.4 ± 179.06 | -289.8 ± 228.03 |
| Month 8 | -263.8 ± 179.38 | -286.1 ± 236.75 |
| Month 9 | -266.7 ± 182.60 | -287.9 ± 237.61 |
| Month 10 | -268.4 ± 173.71 | -282.9 ± 239.98 |
| Month 11 | -270.6 ± 184.34 | -290.3 ± 227.47 |
| Month 12 | -273.4 ± 184.33 | -282.9 ± 233.69 |
Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes
| mm^2 | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 3 | -0.400 ± 0.3576 | -0.026 ± 0.3387 |
| Month 6 | -0.356 ± 0.3983 | -0.055 ± 0.4060 |
| Month 12 | -0.391 ± 0.3716 | -.0208 ± 0.4075 |
Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes
| mm^2 | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 3 | -1.869 ± 1.8071 | 0.111 ± 1.5497 |
| Month 6 | -1.642 ± 1.9570 | -0.078 ± 1.6856 |
| Month 12 | -1.732 ± 1.8059 | -0.823 ± 1.9650 |
Fluorescein leakage area was assessed using Fluorescein angiography (FA) in conjunction with 7-field color fundus photography (CF) at Screening, Month 3, Month 6 and End of Study visit for both eyes
| mm^2 | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Month 3 | -4.994 ± 5.4066 | -0.600 ± 3.6646 |
| Month 6 | -4.654 ± 5.7504 | -0.836 ± 4.2819 |
| Month 12 | -5.078 ± 5.9568 | -2.797 ± 5.3702 |
The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.
| Scores on a Scale | Ranibizumab 0.5 mg | Sham Injection |
|---|---|---|
| Change from Baseline at M3 (n=187,91) | 5.8 ± 10.85 | -1.1 ± 11.21 |
| Change from Baseline at M6 (n=185,88) | 7.7 ± 11.88 | 0.1 ± 13.95 |
| Change from Baseline at M12 (n=176,88) | 9.6 ± 13.45 | 3.3 ± 13.52 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | — | 13/190 (6.8%) | 119/190 (62.6%) |
| Sham With Ranibizumab 0.5 mg | — | 3/66 (4.5%) | 46/66 (69.7%) |
| Sham Without Ranibizumab 0.5 mg | — | 3/26 (11.5%) | 14/26 (53.8%) |
| Event | Ranibizumab 0.5 mg | Sham With Ranibizumab 0.5 mg | Sham Without Ranibizumab 0.5 mg |
|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/190 | 0/66 | 1/26 |
| Cholecystitis chronicHepatobiliary disorders | 0/190 | 0/66 | 1/26 |
| Transient ischaemic attackNervous system disorders | 0/190 | 0/66 | 1/26 |
| Macular holeEye disorders | 0/190 | 1/66 | 0/26 |
| ContusionInjury, poisoning and procedural complications | 0/190 | 1/66 | 0/26 |
| Humerus fractureInjury, poisoning and procedural complications | 0/190 | 1/66 | 0/26 |
| Joint dislocationInjury, poisoning and procedural complications | 0/190 | 1/66 | 0/26 |
| Ulna fractureInjury, poisoning and procedural complications | 0/190 | 1/66 | 0/26 |
| Cluster headacheNervous system disorders | 0/190 | 1/66 | 0/26 |
| HypertensionVascular disorders | 0/190 | 1/66 | 0/26 |
| Event | Ranibizumab 0.5 mg | Sham With Ranibizumab 0.5 mg | Sham Without Ranibizumab 0.5 mg |
|---|---|---|---|
| HypertensionVascular disorders | 16/190 | 8/66 | 4/26 |
| NasopharyngitisInfections and infestations | 23/190 | 8/66 | 3/26 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/190 | 2/66 | 3/26 |
| Conjunctival haemorrhageEye disorders | 20/190 | 4/66 | 0/26 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 2/190 | 0/66 | 2/26 |
| HeadacheNervous system disorders | 11/190 | 2/66 | 0/26 |
| Eye painEye disorders | 10/190 | 1/66 | 0/26 |
| Upper respiratory tract infectionInfections and infestations | 10/190 | 1/66 | 1/26 |
| Intraocular pressure increasedInvestigations | 10/190 | 1/66 | 0/26 |
| Retinal haemorrhageEye disorders | 3/190 | 3/66 | 0/26 |
| Age, Continuous(Years) | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|
| Mean | 57.0 ± 10.14 | 56.8 ± 10.03 | 56.9 ± 10.09 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg | Sham Injection | Total |
|---|---|---|---|
| Female | 101 | 38 | 139 |
| Male | 89 | 55 | 144 |
Ran from Nov 2013 to primary completion in Mar 2016, 28 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 28 months is above that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab